# EDGAR Filing Document

**Accession Number:** 0001382574
**File Stem:** 0000000000-25-008354
**Filing Date:** 2025-8
**Character Count:** 2220
**Document Hash:** 8c080d27089837cdd1e75a3f6967ca86
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008354.hdr.sgml**: 20250923

**ACCESSION NUMBER**: 0000000000-25-008354

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250808

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Scienture Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001382574
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-39199

**BUSINESS ADDRESS:**
- **STREET 1:** 20 AUSTIN BLVD.
- **CITY:** COMMACK
- **STATE:** NY
- **ZIP:** 11725
- **BUSINESS PHONE:** (800) 261 0281

**MAIL ADDRESS:**
- **STREET 1:** 20 AUSTIN BLVD.
- **CITY:** COMMACK
- **STATE:** NY
- **ZIP:** 11725

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRxADE HEALTH, INC
- **DATE OF NAME CHANGE:** 20210602

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRXADE GROUP, INC.
- **DATE OF NAME CHANGE:** 20140207

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XCELLINK INTERNATIONAL INC.
- **DATE OF NAME CHANGE:** 20081230
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001641172-25-000657

## Text-Extract

```

                                                        August 8, 2025

Narasimhan Mani
Co-Chief Executive Officer and President
Scienture Holdings, Inc.
20 Austin Blvd.
Commack, NY 11725

       Re: Scienture Holdings, Inc.
           Form 10-K for Fiscal Year Ended December 31, 2024
           File No. 1-39199
Dear Narasimhan Mani:

       We have completed our review of your filing. We remind you that the
company and
its management are responsible for the accuracy and adequacy of their
disclosures,
notwithstanding any review, comments, action or absence of action by the staff.

                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Life Sciences
cc:   Louis Kern, Esq

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._